This content is in French.
Discovery of vitexin as a novel VDR agonist that attenuates the transition from chronic intestinal inflammation to colorectal cancer
18 septembre 2024
Colitis-associated colorectal cancer (CAC) frequently develops in patients with inflammatory bowel disease (IBD) who have been exposed to a prolonged state of chronic inflammation.
The study of pharmacological agents and their mechanisms for preventing precancerous lesions and inhibiting their progression remains a major objective and challenge in CAC research.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Yonger Chen, Jian Liang, Shuxian Chen, Nan Lin, Shuoxi Xu, Jindian Miao, Jing Zhang, Chen Chen, Xin Yuan, Zhuoya Xie, Enlin Zhu, Mingsheng Cai, Xiaoli Wei, Shaozhen Hou, Hailin Tang
View the source
